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Abstract
Rev-erb α, known as nuclear receptor 1D1 (NR1D1), regulates circadian rhythm, modulates
glucose and lipid metabolism, and inflammatory response. However, little is known about
the effect of Rev-erb agonist on the progression of myocardial infarction (MI) and heart fail-
ure. To investigate it, wild-type male mice underwent sham-operation or permanent ligation
of the left anterior descending coronary artery to create MI model. Rev-erb agonist SR9009
(100 mg/kg/day) or vehicle was intraperitoneally administered. Echocardiography was per-
formed to evaluate cardiac function 1 week after surgery. The gene and protein expression
levels in the left ventricles (LVs) were determined with real-time PCR, western blotting, and
immunofluorescence. Moreover, immune cell infiltration into the LVs was analyzed by flow
cytometry. Survival rate and reduced LV function were significantly improved by the treat-
ment with SR9009 after MI. The expression level and plasma concentration of brain natri-
uretic peptide were significantly lower in MI mice treated with SR9009 (MI+SR) than in MI
mice treated with vehicle (MI+V). Moreover, the mRNA expression levels of inflammatory-
related molecules such as Il6, Mcp1, Ly6g, Cd11b, matrix metallopeptidase (Mmp)9, and
the protein expression levels of phosphorylated NF-κB p65, phosphorylated ERK, and phos-
phorylated p38 were also significantly lower in MI+SR than in MI+V. Immunofluorescence
intensity for MMP-9 was enhanced in the LVs, but was less so in MI+SR than in MI+V. Fur-
thermore, infiltrations of neutrophils and proinflammatory macrophages in the LVs were dra-
matically increased in MI+V and were significantly suppressed in MI+SR. Rev-erb agonist
SR9009 treatment inhibited post-MI mortality and improved cardiac function through modu-
lating inflammation and remodeling process.
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Introduction
As a leading cause of death worldwide, myocardial infarction (MI) remains one of the most
important clinical entities. After the onset of MI, cardiac tissue undergoes sequential molecular
and cellular responses called remodeling [1]. During the acute phase, neutrophils and mono-
cytes are recruited around the necrotic tissue, and they release inflammatory cytokines and
matrix metalloproteinases (MMPs) [2]. Although these processes play important roles in the
degradation of necrotic debris and subsequent scar formation, excess inflammatory response
and MMP overproduction are likely to induce adverse cardiac remodeling, leading to cardiac
dysfunction and rupture [3,4]. Despite the significant progress made on therapeutic strategies
for MI in last few decades, mortality and morbidity remain high, and adverse cardiac remodel-
ing after MI remains a critical issue to be solved. Therefore, continuous improvement in medi-
cations for the disease is still a major concern in global medical research.
Rev-erb belongs to a nuclear receptor superfamily containing two subgroups, Rev-erb α
(NR1D1) and β (NR1D2), that regulate circadian rhythm and modulate glucose and lipid metab-
olism and inflammatory response [5,6]. Recently, SR9009 and SR9011 were developed as syn-
thetic Rev-erb agonists and have been reported to improve hyperglycemia, dyslipidemia, and
skeletal muscle oxidative capacity through modulation of mitochondrial number and oxidative
function [6]. Moreover, long-term treatment with SR9009 was shown to reduce atherosclerotic
plaque by decreasing the ratio of proinflammatory M1 macrophages to anti-inflammatory M2
macrophages in low-density lipoprotein (LDL) receptor-deficient mice fed a Western diet [7].
Thus, Rev-erb is expected to be a promising therapeutic target for metabolic syndrome and ath-
erosclerotic disease. However, little is known about the pathophysiological roles of Rev-erb in
the progression of MI and heart failure.
In this study, we aimed to clarify the roles of Rev-erb in post-MI remodeling and the effects
of Rev-erb agonist SR9009 on cardiac function and survival after MI.
Materials and methods
Mouse model
After receiving approval from the Institutional Animal Experiment Committee of the Univer-
sity of Tsukuba, animal experiments were carried out humanely and in accordance with the
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of
Health, the Regulation for Animal Experiments in our university, and the Fundamental Guide-
line for Proper Conduct of Animal Experiment and Related Activities in Academic Research
Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and
Technology of Japan.
We used 165 male wild-type C57BL6 mice purchased from CLEA Japan, Inc. (Tokyo,
Japan) in total. At 12–14 weeks of age, mice were anesthetized with ketamine and xylazine, fol-
lowed by tracheal intubation and artificial ventilation (MiniVent 845; Harvard Apparatus,
Holliston, MA, USA). Next, a thoracotomy was performed to expose the heart, and MI was
induced by the permanent ligation of the left anterior descending coronary artery (LAD) with
7–0 polypropylene suture passed about 1 mm from the inferior margin of the left atrial auricle.
MI was confirmed by visual observation of myocardial color change and ST-segment elevation
on the electrocardiogram recording. The sham-operated group was subjected to a similar pro-
cedure without ligation of the coronary artery. After closure of the thorax and recovery of
spontaneous breathing, the mice were extubated and placed in a new box on the warm pad for
recovery. Study period was within 2 weeks after surgery, and mice were monitored daily dur-
ing the study. Among 165 mice used for all experiments, 58 mice died before sacrifice (40 mice
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died due to heart failure and/or arrhythmia including operational death, and 18 died due to
cardiac rupture). If mice showed body weight loss of more than 20% and/or significant clinical
signs due to the development of heart failure (e.g., increased respiratory rates, reduced activity,
piloerection, hunched posture), they were immediately euthanized by intraperitoneal injection
of 200 mg/kg sodium pentobarbital. Four mice were euthanized because of cardio-respiratory
distress (weakness, fatigue, deep breathing, dyspnea). Thus, euthanized mice were considered
as death due to heart failure.
SR9009 was purchased from Merck Millipore (Darmstadt, Germany) and was dissolved in
1% dimethyl sulfoxide (DMSO) in normal saline. We started intraperitoneal administration
with SR9009 (100 mg/kg/day, the selection of the doses is based on previous study[7]) or vehi-
cle (1% DMSO in normal saline) from 1 day before surgery. Consequently, mice were divided
into four groups: sham-operated mice treated with vehicle (Sham+V), sham-operated mice
treated with SR9009 (Sham+SR), MI mice treated with vehicle (MI+V), and MI mice treated
with SR9009 (MI+SR). We first investigated mortality over the 14 days after MI and performed
echocardiography at 7 days after MI and just before sacrifice. Next, we excised and collected
the hearts of the mice sacrificed at 3 and 7 days after surgery for RNA and protein extraction
and histochemical analysis, and those of the mice sacrificed at 1 and 5 days after surgery for
flow cytometric analysis. For sacrifice, we used enough volume of sodium pentobarbital.
Echocardiography
We obtained echocardiographic images from the parasternal long-axis view and short-axis
view at the papillary muscle level under anesthesia with isoflurane using a Doppler echocardio-
graphic system (Vevo 2100; Visual Sonics, Toronto, Canada). Accordingly, we determined left
ventricular (LV) end-diastolic diameter (LVDd), LV end-systolic diameter (LVDs), fractional
shortening (FS), LV ejection fraction (LVEF), interventricular septal thickness (IVST), poste-
rior wall thickness (PWT) and LV mass. EF was calculated by the Teichholz method.
Real-time PCR
RNA extraction and gene expression analysis were performed as previously described with
minor modifications [8]. In brief, total RNA was extracted from the LV tissues using a RNeasy
Fibrous Tissue Mini Kit (Qiagen, Venlo, Netherlands), and 2 μg of total RNA was reverse tran-
scribed to cDNA with a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Sci-
entific, Inc., Waltham, MA, USA). The mRNA expression levels of the target genes were
analyzed by an ABI Prism 7500 sequence detection system (Thermo Fisher Scientific). The
commercially available gene-specific primers and probe sets were obtained from Integrated
DNA Technologies (Coralville, IA, USA). The PCR mixture (10 μl total volume) consisted of
primer and probe for each gene at 250 nM, and PrimeTime Gene Expression Master Mix
(Integrated DNA Technologies). PCR amplification was performed in duplicate as follows: 1
cycle at 95˚C for 10 min and 40 cycles at 94˚C for 15 s and 60˚C for 1 min. The primer and
probe used in the study are mentioned as follows: Nr1d1 (Mm.PT.58.17472803), Nr1d2 (Mm.
PT.58.31165809), Nppb (Mm.PT.58.8584045.g), Il6 (Mm.PT.58.10005566), Mcp1 (Mm.
PT.58.42151692), Ly6g (Mm.PT.58.30498043), Itgam (Cd11b) (Mm.PT.5814195622), Mmp9
(Mm.PT.58.10100097), Col1a1 (Mm.PT.58.756.2513), Col3a1 (Mm.PT.58.13848686). The
quantitative values of target mRNA were normalized by 18S rRNA (4319413E, Thermo Fisher
Scientific) expression. The results were obtained from 2–3 independent measurements (n = 4
in each group) performed in duplicate.
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Enzyme Immunoassay (EIA) for BNP
Plasma BNP concentration was measured by using a Brain Natriuretic Peptide EIA Kit
(RAB0386-1KT, Sigma-Aldorich, Inc., St. Luise, MO, USA) according to the procedural man-
ual. In brief, the samples and standards mixed with 10 pg/ml of biotinylated BNP peptide were
added to the anti-BNP antibody-immobilized plate, where the biotinylated BNP peptide com-
peted with unlabeled (endogenous) BNP for binding to the antibody. After incubating plate at
4˚C overnight and washing wells, horseradish peroxidase (HRP)-streptavidin solution was
added to each well, and incubated for 45 minutes at room temperature. After washing, tetra-
methylbenzidine (TMB) solution was then added to each well to visualize the immunoreac-
tion. After adding stop solution, absorbance of each well was measured by using Varioskan
LUX microplate reader (ThermoFisher) at 450nm. The result was obtained from one measure-
ment (n = 4 in each group) performed in duplicate.
Histology and immunofluorescence
The hearts were fixed with 4% paraformaldehyde, embedded in paraffin, sectioned into 4-μm-
thick slices, and stained with Masson’s trichrome. Images were obtained by a digital micro-
scope (Biozero BZ-X700; Keyence, Osaka, Japan), and collagen deposition was calculated by
dividing the collagen depositing area to the total area. The analysis was performed using the
ImageJ analysis software (Ver. 1.45, NIH, USA).
To evaluate the expression of MMP-9 on day 3, we performed immunofluorescence. After
deparaffinization and antigen activation, sections were incubated with polyclonal rabbit anti-
MMP9 antibodies (ab38898; Abcam, Cambridge, UK) at 4˚C overnight. Next, sections were
sufficiently rinsed in PBS and then incubated to Alexa Fluor 594-labeled goat anti-rabbit IgG
(Thermo Fisher Scientific) at room temperature for 2 hours. After rinsing in PBS and mount-
ing on slides with mounting medium with DAPI, the fluorescent images were captured by a
digital fluorescent microscope (Biozero BZ-X700). The ratio of Alexa Fluora 594-positive area
to total area was calculated with the ImageJ analysis software.
Flow cytometry
Heart inflammatory cells were isolated and processed as described previously [9]. In brief, 1
and 5 days after MI or sham operation, hearts were excised, cut roughly, and dissociated by
using gentleMACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) in HBSS
mixed with hyaluronidase, collagenase, and DNase I in accordance with the experimental pro-
tocol. Next, the cells were rinsed with PBS, dissolved with MACS buffer (Miltenyi Biotec), and
passed through cell strainer (70μm) (Corning Inc., Corning, NY, USA). After removing red
blood cells by ACK lysing buffer (Lonza Japan, Ltd., Tokyo, Japan), the cells were directly
stained with fluorescence-conjugated antibodies as follows: FITC-conjugated anti-mouse Ly6g
antibody, PE-conjugated anti-mouse CD11b antibody, and APC-conjugated anti-mouse
CD45.2 antibody. To differentially investigate M1/M2 macrophages, the cells collected from
mice 5 days after surgery were also stained with FITC-conjugated anti-mouse F4/80 antibody,
PE-conjugated anti-mouse CD11b antibody, and APC-conjugated anti-mouse CD206 anti-
body. After 1 hour incubation at 37˚, the cells were rinsed with PBS, diluted with MACS buffer,
mixed with DAPI, and analyzed with a FACSCalibur instrument (Becton Dickinson Co.,
Franklin Lakes, NJ, USA), followed by analysis with FlowLogic software (Inivai Technologies,
Mentone, Victoria, Australia). All antibodies were obtained from Bay Bioscience (Brookline
MA, USA), Biolegend Inc., (San Diego, CA, USA), or Amersham Biosciences Corp., (Bucking-
hamshire, United Kingdom).
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Western blotting analysis
Western blotting was performed as described previously [8]. In brief, isolated LVs were
homogenized in PRO-PREP protein extraction solution (iNtRON Biotechnology, Inc.
Kyungki-Do, Korea), and the supernatants were used for western immunoblotting. Appropri-
ate volumes of the samples (10 μg) were mixed with an equal volume of sample buffer, heated
at 95˚C for 5 min, and then subjected to SDS-PAGE using 4–15% gradient polyacrylamide gels
(Bio-Rad Laboratory, Hercules, CA, USA). The proteins were transferred by semidry electro-
blotting from gels to polyvinylidene difluoride membranes. The blots were then blocked with
the primary antibodies as follows: phospho-NF-κB p65 (Ser536 (#3033) and Ser468 (#3039)),
NF-κB (L8F6) (#6956), phospho-p38 (Thr180/182) (#9211S), p38 mitogen activated protein
kinase (MAPK) (#9212), phospho-p44/42 MAPK (Thr202/Thr204) (#9101S), p44/42 MAPK
(#9102), β-actin (#4967) (all were purchased from Cell Signaling Technology, Inc., Danvers,
MA, USA), and Rev-erb α (RS-14) (sc-100910, Santa Cruz Biotechnology, Inc, Dallas, TX,
USA). The blots were incubated with an appropriate second antibody, horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (ab6721, Abcam) or HRP-conjugated rabbit anti-
mouse IgG (ab97046, Abcam). Immunoreactions were visualized with an enhanced chemilu-
minescence method (ECL Prime Western Blotting Detection; GE Healthcare, Southeast, UK).
Densitometric analysis was performed on scanned immunoblot images with the ImageJ analy-
sis software (Ver.1.45, NIH, USA). The ratios of densities of bands detected by using phos-
phorylated antibodies to those detected by using nonphosphorylated (total) antibodies or β-
actin antibody was obtained from 2–3 independent measurements (n = 3 per group for each
measurement).
Statistical analysis
All data are expressed as mean ± SEM. Experimental groups were compared by one-way analy-
sis of variance followed by Bonferroni’s test for multiple comparisons. When the results were
not normally distributed, statistical analyses were performed using Kruskal-Wallis one-way
analysis of variance. The effect of SR9009 on the survival of mice was analyzed by Kaplan-
Meier methods and compared by log-rank test. Differences were considered statistically signif-
icant at p< 0.05. The analysis was performed using IBM SPSS version 21.0 software (IBM Co.,
Armonk, NY, USA).
Results
MI affects the expression of Rev-erb at mRNA and protein levels
First, we investigated the gene and protein expressions of Rev-erb in the LVs after MI. The
mRNA expression level of Rev-erb α in the LVs was slightly changed but not significantly dif-
ferent between sham, day 3, and day 7 after MI (Fig 1A). The protein expression level of Rev-
erb α was slightly increased on day 3 whereas it was significantly decreased on day 7 after MI
(Fig 1C). On the other hands, the mRNA expression level of Rev-erb β was significantly
decreased on day 3 and 7 after MI (Fig 1B).
SR9009 suppresses post-MI mortality and improves cardiac function
We next investigated survival after MI with or without SR9009 treatment. After permanent
ligation of the LAD in 58 mice (38 in MI+V; 20 in MI+SR), 18 mice (15 in MI+V; 3 in MI+SR)
died because of ventricular rupture that occurred between 3 and 7 days after MI. Meanwhile,
16 mice (11 in MI+V; 5 in MI+SR) died without bleeding in the thoracic cavity. We assumed
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they died either due to acute heart failure or cardiac arrhythmia. The survival rate of MI+V
group was 31.6%, while it was significantly higher in MI+SR (60.0%, log-rank p<0.05; Fig 2).
To assess cardiac function after MI, we performed echocardiographic analysis 7 days after
surgery in each group (Fig 3A–3D). Echocardiographic analysis revealed that SR9009
Fig 1. Gene and protein expression levels of Rev-erb in the left ventricular (LV) border area after myocardial infarction (MI). (A) The
expression level of Rev-erb αmRNA in the LV was not significantly different between sham, 3 days, and 7 days after MI (n = 4 animals for
each time point). (B) The expression level of Rev-erb βmRNA in the LV was significantly decreased 3 and 7 days after MI (n = 4 animals for
each time point). (C) Western blotting analysis showed a significant decrease in the expression level of Rev-erb α 7 days after MI (n = 3
animals for each time point). The bar graphs show the group mean±SEM. *p<0.05 vs Sham.
https://doi.org/10.1371/journal.pone.0189330.g001
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treatment significantly improved LVEF and FS (Table 1.). LVDd, Ds, and LV mass were
slightly lower in MI+SR, but these were not significantly different between MI+V and MI+SR
(Table 1.). The ratios of heart weight to BW, LV weight to BW, and lung weight to BW were
not significantly different between MI+V and MI+SR (Table 1.).
SR9009 does not affect collagen deposition after MI
Representative photomicrographs of LV tissues are shown in Fig 4A–4D. LV size and wall
thickness were similar between Sham+V and Sham+SR. Although collagen deposition was
observed in large areas of the LV of both MI+V and MI+SR, there were no obvious histological
differences between the two groups. Quantitative analysis revealed that there was no signifi-
cant difference in collagen depositing area between MI+V and MI+SR (Fig 4E). LV gene
expression levels of Col1a and Col3a were markedly upregulated 7 days after MI. SR9009 treat-
ment reduced the Col1a expression, but there were no significant differences in mRNA expres-
sion levels of Col1a and Col3a between MI+V and MI+SR (Fig 4F and 4G).
SR9009 inhibits the expressions of natriuretic peptide, inflammatory
cytokines, and MMP-9
We investigated mRNA expression levels in the LV by using real-time PCR. The mRNA
expression level of natriuretic peptide precursor B, which encodes a marker of heart failure
Fig 2. Kaplan-Meier survival curves after myocardial infarction. Survival rate was significantly higher in MI+SR than in MI+V
(60.0% vs 31.6% at day 14 after myocardial infarction; log-rank test, p = 0.032 compared between MI+SR and MI+V). Solid line
denotes the survival curve of MI+V and dashed line denotes of MI+SR.
https://doi.org/10.1371/journal.pone.0189330.g002
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brain natriuretic peptide (Bnp), was 8-fold higher in MI+V compared to Sham+V, and it was
significantly lower in MI+SR than in MI+V (Fig 5A). Moreover, the left ventricular expression
levels of inflammatory cytokines Il6 and Mcp1, neutrophil-related surface antigen Ly6g, and
monocyte/macrophage-related surface antigen Cd11bwere increased after MI, and these levels
were dramatically decreased by SR9009 treatment (Fig 5B–5E). The mRNA expression level of
Mmp9, a major extracellular matrix protein playing a critical role in post-MI remodeling, was
also increased in MI+V and was significantly decreased in MI+SR compared with MI+V (Fig
5F). Moreover, plasma BNP concentration was also significantly higher in MI+V than in Sham
+V, and it was significantly lower in MI+SR than in MI+V (Fig 5G). These results suggested
that elevated BNP, infiltration of neutrophils and monocytes/macrophages, and productions
of inflammatory cytokines and extracellular matrix were reduced by the treatment with
SR9009 during the acute phase of MI.
To confirm the protein expression level of MMP-9, we performed immunofluorescence.
Immunofluorescence intensity for MMP-9 could be weakly detected in both of the sham
groups, and it was enhanced mainly in the interstitial tissue of the border area after MI. MI
+SR displayed less intensity of MMP-9 compared to that in MI+V (Fig 6). Quantitative analy-
sis revealed that significant increase in immunofluorescence-positive area in MI+V was
reduced by SR9009 treatment.
Fig 3. M-mode echocardiographic analysis. The representative M-mode findings of the left ventricular
short-axis view on day7 after MI: (A) Sham+V, (B) Sham+SR, (C) MI+V, and (D) MI+SR.
https://doi.org/10.1371/journal.pone.0189330.g003
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SR9009 reduces infiltration of neutrophils and M1 macrophages into the
infarcted myocardium
To further investigate the effect of SR9009 on the infiltration of inflammatory cells into the LV
during the acute phase of MI, we performed flow cytometric analysis. CD45+CD11b+Ly6G
+ cells (neutrophils) were dramatically increased in the heart 1 day after MI from MI+V com-
pared to Sham+V (Fig 7A and 7B). SR9009 treatment decreased the infiltrations of CD45
+CD11b+Ly6G+ cells 1 day after MI (Fig 7C). Quantitative analysis revealed a significant
decrease in the percentage of CD45+CD11b+Ly6G+ cells to CD45+ cells (Fig 7D). These
results suggested that neutrophil influx was reduced by the treatment with SR9009 during the
acute phase.
We next investigated the infiltrations of M1/M2 macrophages in the heart 5 days after MI.
The percentage of CD11b+F4/80+CD206+ cells (M2 macrophages) to live cells was not signifi-
cantly different between MI+V and MI+SR 5 days after MI; however, the percentage of CD11b
+F4/80+CD206- cells (M1 macrophages) to live cells was significantly lower in MI+SR than in
MI+V (Fig 7E–7H).
SR9009 modulates NF-κB and MAPKs signalling pathway in the LV
Rev-erb α has been reported to repress cytokine productions not only directly through a
Rev-erb α-binding motif but also indirectly through NFκB- and/or MAPK-signaling path-
way [10,11]. Therefore, we performed western blotting to evaluate whether SR9009 treat-
ment influenced NF-κB and MAPKs in the LV after MI. SR9009 treatment suppressed the
expression of serine 468-phosphorylated (S468) and serine 536-phosphorylated (S536) NF-
κB p65 (Fig 8A). Quantitative analysis revealed that the ratio of phospho-NF-κB p65 (S468)
to NF-κB p65 was significantly lower in MI+SR than in MI+V (Fig 8B). SR9009 treatment
Table 1. Tissue weights and echocardiographic parameters.
Sham+V Sham+SR MI+V MI+SR
n = 4 n = 4 n = 9 n = 7
BW 24.02±0.62 25.35±0.23 23.77±0.75 23.39±0.83
Heart 125.8±2.45 139.45±6.55 157.38±9.42* 148.97±13.46
HW/BW 5.24±2.45 5.49±0.24 6.78±0.46* 6.30±0.40
LV/BW 4.29±0.05 4.44±0.15 5.42±0.36* 5.35±0.51*
Lung/BW 5.38±0.21 5.19±0.13 8.25±1.08* 7.20±0.87*
LVDd (mm) 3.16±0.19 2.78±0.24 5.25±0.21* 4.88±0.26*
LVDs (mm) 2.13±0.23 1.87±0.30 4.97±0.24* 4.36±0.30*
FS (%) 31.67±4.74 32.29±4.10 6.23±0.92* 11.07±2.04*†
EF (%) 64.67±7.66 61.71±6.27 13.85±2.02* 23.78±4.21*†
IVST (mm) 0.725±0.02 0.69±0.11 0.67±0.06 0.74±0.03
PWT (mm) 0.62±0.10 0.90±0.07 0.68±0.04 0.60±0.11
LV Mass (mg) 83.12±12.11 85.72±11.72 156.02±21.33* 147.30±11.64*
LV ejection fraction (EF) and fractional shortening (FS) were significantly higher in MI+SR than in MI+V, whereas LV end-diastolic diameter (LVDd), LV end-
systolic diameter (LVDs) and LV mass were not significantly different between MI+V and MI+SR, and the ratios of heart weight to BW, left ventricular (LV)
weight to BW, and lung weight to BW were also not significantly different between MI+V and MI+SR (n = 4 in each sham group, n = 9 animals in MI+V group,
and n = 7 animals in MI+SR group). The bar graphs show the group mean±SEM.
*p<0.05 vs Sham+V
†p<0.05 vs MI+V
https://doi.org/10.1371/journal.pone.0189330.t001
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also suppressed phosphorylations of p38 and p44/42 (ERK) (Fig 8A). The ratios of phos-
phorylated p38 to p38 and phosphorylated ERK to ERK were significantly lower in MI+SR
than in MI+V (Fig 8D).
Fig 4. Representative photographs of the left ventricles at papillary muscle level. (A) Sham+V, (B) Sham+SR, (C) MI+V, and (D) MI+SR. (E)
shows the ratio of collagen depositing area to total area. There was no significant difference in collagen deposition between MI+V and MI+SR (n = 4
animals in each group). (F) The mRNA expression level of collagen type Ia1 (Col1a) was significantly increased in MI+V, and was tend to be decreased
in MI+SR, but not significantly different between MI+V and MI+SR. (G) The mRNA expression level of collagen type IIIa1 (Col3a) was also significantly
increased in MI+V, and was not significantly different between MI+V and MI+SR (n = 4 animals in each group).
https://doi.org/10.1371/journal.pone.0189330.g004
Rev-erb agonist improves post-MI remodeling
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Discussion
In this study, we showed for the first time, to our knowledge, that Rev-erb agonist SR9009
improved LV function and survival after MI. Moreover, we also showed that Rev-erb agonist
decreased Il6 and Mcp1 production, Mmp9 expression, NF-κB and MAPKs activations, and
Fig 5. Gene expression levels of the left ventricles analyzed by real-time PCR and plasma BNP concentration. (A) The mRNA expression
level of natriuretic peptide precursor B (Nppb) was significantly higher in MI+V than in sham, and was significantly lower in MI+SR than in MI+V (n = 4
animals in each group). The expression levels of (B) Il6, (C) Mcp1, (D) Ly6g, and (E) Cd11b were significantly increased in MI+V and were markedly
decreased in MI+SR. (F) Matrix metallopeptidase (Mmp)9 was also significantly lower in MI-SR than in MI-V. (G) Plasma BNP concentration was also
significantly higher in MI than in sham, and was significantly lower in MI+SR than in MI+V. The bar graphs show the group mean±SEM. *p<0.05 vs
Sham+V; †p<0.05 vs MI+V.
https://doi.org/10.1371/journal.pone.0189330.g005
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Fig 6. Representative immunofluorescence images of the left ventricles stained with MMP-9. (A) Sham+V, (B) Sham+SR,
(C) MI+V, and (D) MI+SR. MMP-9 was stained with Alexa Fluor 594 (red) and nuclei were stained with DAPI (blue). All images
show 40×magnification. Sham groups showed low immunofluorescence intensity, and MMP-9 was strongly detected in the infarct
and border areas in the MI groups. MI+SR showed less intensity compared with MI+V. (E) The ratio of immunofluorescence-
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neutrophil/M1 macrophage infiltrations in infarct and border myocardium during the acute
phase of MI. These results suggested that the pharmacological activation of Rev-erb exerts ben-
eficial effects on the acute process of post-MI remodeling by strongly inhibiting cytokine pro-
duction and inflammatory cell infiltration into the infarcted heart.
Inflammatory response after MI is a double-edged sword, and how to regulate inflamma-
tion to prevent adverse cardiac remodeling is an important issue to be considered when devel-
oping a new treatment for heart failure [12–14]. In the present study, we showed that the
expression levels of inflammatory cytokines including Mcp1 and Il6 were dramatically sup-
pressed by SR9009 treatment in the LV during the acute phase of MI, and that of Mmp9 was
also suppressed by SR9009 treatment. Moreover, we also showed that NF-κB and MAPKs acti-
vation were inhibited by the treatment with SR9009. These findings are consistent with the pre-
vious studies [10,11,15,16]. Sato et al. reported that activated Rev-erb α repressed Il6 expression
not only directly through a Rev-erb α binding motif but also indirectly through suprression of
NF-κB activity [10]. They also reported that Rev-erb α regulated the inflammatory function of
macrophages through suppression of MCP-1-acitivating ERK and p38 signalling pathway [11].
Il6 receptor antagonist has been reported to reduce leukocyte and macrophage infiltration and
attenuate MMP activation, leading to a marked improvement in LV remodeling and survival
after MI [17]. Moreover, targeted deletion of Mcp1 attenuated LV remodeling after MI through
decreases in macrophage infiltration and MMP activation [18,19]. MMP-9 is known as a
major subtype of metalloproteinase and plays a crucial role in post-MI remodeling. In the
acute inflammatory phase after MI, neutrophils and monocytes are considered to be the
predominant source of MMPs. Higher production of MMPs is more likely to cause LV wall
thinning and dilatation, consequently leading to heart failure and cardiac rupture. It has
been reported that genetic and pharmacological deletion of MMP-9 prevents adverse LV
remodeling after MI [20,21]. Moreover, previous study reported that Rev-erbs repressed
MMP-9 expression at a distance by regulating enhancer-directed transcription [16]. Thus,
the present study, taken together with the findings of previous reports, suggests that the
strong inhibitory effect of SR9009 on the production of inflammatory cytokines such as Il6
and Mcp1 attenuates neutrophil and M1 macrophage infiltrations and MMP-9 production,
at least partially through suppression of NF-κB, ERK, or p38 signalling pathway, leading
to inhibition of the vicious circle of proinflammatory amplification, the development of
adverse LV remodeling, and cardiac rupture.
MAPKs are known as important signaling pathway that regulates cell survival, apoptosis,
and proliferation. In the present study, phosphorylated ERK and phosphorylated p38 were sig-
nificantly decreased by SR9009 treatment in the LV after MI. ERK activation is thought to
inhibit apoptotic loss of cardiomyocytes and promote cardiac fibrosis. On the other hands,
p38 activation has been implicated in the progression of apoptosis and cardiac dysfunction,
leading to pathological remodeling although still controversial [22].
Despite a significant improvement of LV function by SR9009 treatment, there was no sig-
nificant difference in collagen deposition between MI+V and MI+SR. The size of collagen
deposition area is mainly determined by the size of the necrotic area, the wound healing
response, and chronic remodeling [23]. Among them, the size of the necrotic area is the most
critical for determination of the scar size in acute phase of MI, especially without reperfusion.
Because we employed mice model with the permanent ligation of the proximal LAD in this
study, necrotic area was relatively extensive and generally constant in each mouse. Therefore,
positive area to total area was significantly increased in MI+V, and was markedly decreased in MI+SR (n = 4 animals in each
group). The bar graphs show the group mean±SEM. *p<0.05 vs Sham+V; †p<0.05 vs MI+V.
https://doi.org/10.1371/journal.pone.0189330.g006
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Fig 7. Flow cytometric analysis. Flow cytometric analysis of the infiltration of inflammatory cells into the infarct and border areas at 1 day after myocardial
infarction (MI) (n = 5 in each group). The representative plots (gated on CD45+ and expanded into Ly6G and CD11b) of (A) Sham+V, (B) MI+V, and (C) MI
+SR9009 are shown. (D) The percentage of CD45+CD11b+Ly6G+ cells (neutrophils) to CD45+ cells was significantly lower in MI+SR than in MI+V,
suggesting that neutrophil infiltration was reduced by SR9009 treatment. Flow cytometric analysis of M1/M2 macrophage infiltration into the infarct and
border areas at 5 days after MI (n = 5 in each group). The representative plots (gated on CD11b and expanded into F4/80 and CD206) of (E) MI+V, and (F)
MI+SR9009 are shown. (G) The percentage of F4/80+CD206- cells to live cells was significantly lower in MI+SR than in MI+V although the percentage of
F4/80+CD206+ cells to live cells was not significantly different between MI+V and MI+SR, suggesting that proinflammatory M1 macrophage infiltration was
reduced by SR9009 treatment. The bar graphs show the group mean±SEM. *p<0.05 vs Sham+V; †p<0.05 vs MI+V.
https://doi.org/10.1371/journal.pone.0189330.g007
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Fig 8. Western blotting analysis. (A) Representative images of western blotting for phospho-NF-κB p65 (S468 and S536), NF-κB, phospho-p38, p38,
phospho-ERK, ERK, and β-actin. (B) The ratio of phospho-NF-κB (S468) to NF-κB was significantly lower in MI+SR than in MI+V. (C) The ratio of
phospho-NF-κB (S536) to NF-κB had a similar tendency, but no significant difference. (D) The ratio of phospho-p38 to p38 was significantly lower in MI
+SR than in MI+V. (E) The ratio of phospho-ERK to ERK was also significantly lower in MI+SR than in MI+V. (n = 3 animals in each group). The bar
graphs show the group mean±SEM. *p<0.05 vs Sham+V; †p<0.05 vs MI+V.
https://doi.org/10.1371/journal.pone.0189330.g008
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the area of collagen deposition was mostly influenced by the size of necrotic area with or with-
out treatment. However, because histological data were only obtained from the samples col-
lected within 1 week after MI, further studies are needed to evaluate the effect of Rev-erb
agonist in collagen deposition in chronic phase of MI.
Rev-erb α regulates not only inflammation but also mitochondrial content and oxidative
capacity. It has been reported that expression levels of phosphorylated AMPK, sirtuin 1,
PPAR-gamma coactivator (PGC)-1α, and mitochondrial transcription factor A (TFAM) were
significantly lower in the skeletal muscle from homogenous Nr1d1-knockout (Nr1d1-/-) mice
compared to wild-type mice [6]. Consequently, mitochondrial DNA content was significantly
lower in skeletal muscle from Nr1d1-/- mice, and VO2 max during exercise was significantly
lower in Nr1d1-/- than in wild-type mice. By contrast, pharmacological activation or skeletal
muscle-specific Rev-erb α overexpression resulted in the opposite phenotypes. These findings
suggested that Rev-erb α controls mitochondrial biogenesis and respiration in the skeletal
muscle through the Ampk-Sirt1–Pgc1α-Tfam signaling pathway. Several studies reported that
activation of AMPK, such as treatment with metformin, protects the heart against cardiac
stress such as ischemia by regulating glucose and fatty acid metabolism [24,25]. Therefore,
favorable effects of Rev-erb agonist SR9009 on cardiac function may be partially attributed to
activation of this pathway and modulation of the metabolic process[26–30]. Further studies
are needed to clarify the effect of the Rev-erb agonist on cardiac metabolism after MI, espe-
cially during the chronic phase.
SR9009 and SR9011 were synthesized as novel Rev-erb agonists, and they have been
reported to improve hyperglycemia, dyslipidemia, and skeletal muscle oxidative capacity by
modulating mitochondrial number and oxidative function in mice [6]. Moreover, long-term
treatment with SR9009 could reduce atherosclerotic plaque by decreasing the ratio of pro-
inflammatory M1 macrophages to anti-inflammatory M2 macrophages in LDL receptor-defi-
cient mice fed a Western diet [7]. In terms of clinical implications, the present study, taken
together with the previous reports, suggested that Rev-erb agonists can be expected to be
promising novel drugs not only for metabolic syndrome and atherosclerotic disease but also
for MI and heart failure. For example, the drugs may be useful for secondary prevention in
patients with MI complicated with metabolic syndrome.
The present study included the following limitations. First, we only studied the acute phase
of MI using a mouse model with permanent ligation of the coronary artery. Further studies are
needed to elucidate the long-term effects of Rev-erb agonist and/or in an ischemia/reperfusion
model. Second, although we administered only one dose of SR9009 (100 mg/kg/day) according
to the previous study [5], we may need another dose to investigate whether dose dependency
exists. Moreover, we tried to start the treatment with SR9009 on the next day after MI surgery;
however, the survival rate and LV function did not reach significant improvement. Longer
periods of severe ischemia (usually more than 6-hour ischemia due to complete coronary
occlusion) is considered to cause loss of most cardiomyocytes in the subendocardial region of
the ischemic area [31]. “Late-start treatment” with SR9009 may not exert enough inhibitory
effects on cardiac cell death although a single injection of 100mg/kg of SR9009 quickly alters
circadian pattern and metabolic gene expressions in mice [5]. As clinical implications, Rev-erb
agonists may be useful for secondary prevention in patients with prior MI or metabolic syn-
drome with high risk for coronary artery disease although late-start treatment with Rev-erb
agonist after the onset of MI may not be enough to improve clinical prognosis. Third, this
study suggested that the favorable effect of SR9009 on post-MI remodeling was mainly attrib-
uted to the strong attenuations of inflammatory cytokine production and MMP-9 production.
However, another mechanism such as alteration of metabolic processes and/or circadian
rhythm may contribute to the results. Further studies are desirable to investigate the precise
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mechanism of the effect of Rev-erb activation on post-MI remodeling using antagonist or
gene-manipulated mice models.
In conclusion, Rev-erb agonist SR9009 could improve cardiac function and survival in a
mouse model of acute MI by inhibiting cytokine production and inflammatory cell infiltration.
Rev-erb α is expected to be a promising therapeutic target not only for metabolic syndrome
and atherosclerotic disease but also for MI and heart failure.
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